Keyphrases
Response to Therapy
100%
Metastatic Breast Cancer
100%
Poor Response
100%
Circulating Tumor Cells
100%
Phenotypic Plasticity
100%
Circulating Tumor Cell Count
54%
Gene Expression
36%
Progressors
27%
Multivariate Analysis
18%
Epithelial Markers
18%
Triple-negative Status
18%
Gene Expression Profiling
9%
High Risk
9%
Overall Survival
9%
Progression-free Survival
9%
Univariate Analysis
9%
Clinical High Risk
9%
Fibroblast Growth Factor Receptor 1 (FGFR1)
9%
Single Center
9%
Risk of Progression
9%
Blood Draw
9%
Sectional Analysis
9%
Image Analysis
9%
3-month Follow-up
9%
Cellular Expression
9%
Metastatic Spread
9%
Mesenchymal Markers
9%
Nonprogressors
9%
Agnostic
9%
Metastatic Progression
9%
Prognostic Utility
9%
Treatment Line
9%
Enrichment Analysis
9%
Circulating Tumor Cells Enrichment
9%
Multimodality Analysis
9%
Microcavity Array
9%
Biochemistry, Genetics and Molecular Biology
Cell Count
100%
Phenotypic Plasticity
100%
Gene Expression
66%
Multivariate Analysis
33%
Overall Survival
16%
Gene Expression Profiling
16%
Fibroblast Growth Factor Receptor 1
16%
Progression Free Survival
16%
Cross Sectional Study
16%
Immunology and Microbiology
Circulating Tumor Cell
100%
Phenotypic Plasticity
100%
Cell Count
33%
Gene Expression
22%
Gene Expression Assay
5%
Overall Survival
5%
Fibroblast Growth Factor Receptor 1
5%
Progression Free Survival
5%